| Name | Title | Contact Details |
|---|
Enalare Therapeutics Inc. is a privately owned clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions.
Opiant Pharmaceuticals` team of industry and addiction experts are dedicated developing treatments for addiction, overdose, and related disorders for the mass market. Our first product NARCAN® Nasal Spray became available in the United States and Canada through our commercial partner, Adapt Pharma.
At Merrimack, researchers, clinicians, professionals, and, yes, engineers work together in a multidisciplinary, team-based environment. All are committed to a single vision. Building cures for cancer.
Regulatory compliance software solutions, products and services assist pharmaceutical, medical device and biotechnology companies in complying with marketing and sales regulations.
Context Therapeutics Inc. (Nasdaq: CNTX) is a women`s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company`s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a novel small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women`s cancers.